 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910111213...1516» |
- Incidence of cardiometabolic outcomes among people living with HIV initiated on INSTI versus non-INSTI antiretroviral therapies () - May 12, 2022 - Abstract #AIDS2022AIDS_700;
Among treatment-naïve PWH in the US, INSTI initiation was associated with greater risk of developing congestive heart failure, myocardial infarction, and lipid disorders during a short follow-up period. With increasing life expectancy among PWH, further research including additional clinical variables and using longer follow-up is warranted to examine the impact of INSTI-containing ART on long-term clinical outcomes.
- | Pifeltro (doravirine) / Merck (MSD)
Journal: Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients. (Pubmed Central) - May 6, 2022
The frequency of transmitted drug resistance to DOR is low, allowing for effective treatment of antiretroviral treatment-naïve patients and rapid treatment initiation. In cART-experienced patients, this agent remains an attractive NNRTI option with a higher genetic barrier to resistance.
- | Tybost (cobicistat) / Gilead, Prezista (darunavir) / J&J, Edurant (rilpivirine) / J&J
Journal: Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial. (Pubmed Central) - May 6, 2022
P4
In cART-experienced patients, this agent remains an attractive NNRTI option with a higher genetic barrier to resistance. The combination of rilpivirine plus darunavir/cobicistat sustained virological suppression, was associated with a low frequency of virological failure, and had a favorable safety profile, which support its use as a nucleoside reverse transcriptase inhibitor-sparing and integrase inhibitor-sparing alternative to three-drug regimens.
- || Edurant (rilpivirine) / J&J
P2b data, Journal, Combination therapy: Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies. (Pubmed Central) - May 6, 2022
RPV 25 mg QD in combination with an investigator-selected background regimen of two NRTIs demonstrated sustained long-term virologic suppression. The treatment was well-tolerated with no new safety findings.
- | Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study. (Pubmed Central) - May 6, 2022
The treatment was well-tolerated with no new safety findings. Dolutegravir-based 2DR showed high virological efficacy and durability, however past resistance increased the risk of VF, but not of TD or TF.
- || Edurant (rilpivirine) / J&J, rilpivirine oral suspension (SACT-1) / Aptorum Group
New P1 trial: A Study of Bioavailability and Food Effect of SACT-1 and Edurant (clinicaltrials.gov) - May 2, 2022
P1, N=16, Completed, Sponsor: Aptorum International Limited
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vitekta (elvitegravir) / Japan Tobacco, Gilead
Journal: Reduction of CD8 T cell functionality but not inhibitory capacity by integrase inhibitors. (Pubmed Central) - Apr 29, 2022
In summary, our study provides first evidence on a significant, negative impact on CD8 T cell effector functions in the presence of two INSTIs, dolutegravir and elvitegravir, which may contribute to the limited success of eradicating HIV-infected cells through "shock-and-kill" strategies. Although our findings are coherent with recent studies highlighting a possible role of dolutegravir in weight gain, further investigations are necessary to fully understand the impact of INSTI-based regimens on the health of the individual during antiretroviral therapy.
- | Edurant (rilpivirine) / J&J
Journal: Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less. (Pubmed Central) - Apr 28, 2022
Finally, we also provide evidence that RPV compromises the viability of TGF-β-induced HSC independently of its antifibrogenic effect, observed as reduced collagen 1A1 synthesis, and that this effect does not include RPV´s modulation of autophagy. In summary, as a contributor to the mechanisms involved in the hepatoprotective action of RPV, autophagy may be a good candidate to explore when developing novel therapeutics for LF.
- ||| Edurant (rilpivirine) / J&J
Reimbursement: Carbo/rilpivirine will be my go to. More easy to get than other options but also running into insurance push back depending on provider. It is between 5000$ -6000$ a month 🤷🏽♀️ (Twitter) - Apr 16, 2022
- | Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Journal: Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort. (Pubmed Central) - Apr 12, 2022
In summary, as a contributor to the mechanisms involved in the hepatoprotective action of RPV, autophagy may be a good candidate to explore when developing novel therapeutics for LF. In the real world, the risks of discontinuation due to TF and VF were more than two times higher in patients switching to DTG-based 2DR than INSTI-based 3DR, with no difference in discontinuation due to AEs.
- | Edurant (rilpivirine) / J&J
Trial completion date, Trial primary completion date, HEOR, Real-world evidence: 'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor (clinicaltrials.gov) - Apr 11, 2022
P=N/A, N=1, Recruiting, Sponsor: ViiV Healthcare
In the real world, the risks of discontinuation due to TF and VF were more than two times higher in patients switching to DTG-based 2DR than INSTI-based 3DR, with no difference in discontinuation due to AEs. Trial completion date: Dec 2021 --> Jan 2023 | Trial primary completion date: Dec 2021 --> Jan 2023
- | Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Journal: Patients' experiences and opinions after de-simplification of their single-tablet regimens for the treatment of HIV infection: a survey in a multicentre cohort. (Pubmed Central) - Apr 9, 2022
After STR de-simplification, most patients had a fair knowledge about generic antiretrovirals , and they agreed to de-simplify their STR in order to decrease costs. Although almost a third of the respondents were not happy to take two pills a day, only a minority reported worse adherence or quality of life.
- | Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Preclinical, Journal: HPLC-MS method for simultaneous quantification of the antiretroviral agents rilpivirine and cabotegravir in rat plasma and tissues. (Pubmed Central) - Apr 6, 2022
The presented method was selective, sensitive, accurate and precise for detection and quantification of RPV and CAB in all matrices. The developed and validated bioanalytical method was successfully employed for in vivo samples with both drugs simultaneously.
- | Pifeltro (doravirine) / Merck (MSD)
Journal: Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014-18. (Pubmed Central) - Apr 2, 2022
In China, the prevalence of doravirine cross-resistance among patients who have failed first-line ART is high. Therefore, doravirine should not be used blindly without genotypic resistance testing and is not recommended for people who have failed first-line NNRTI-based ART.
- || Edurant (rilpivirine) / J&J
Clinical, P2 data, Journal: Long-term safety, tolerability and antiviral activity of rilpivirine in antiretroviral-naïve adolescents living with HIV-1, aged 12 to less than 18 years: Week 240 findings of a phase 2, open-label study, PAINT. (Pubmed Central) - Mar 23, 2022
P2
RPV exhibited favorable long-term safety profile for adolescents living with HIV-1 with adequate adherence. Clinical Trial Number: NCT00799864.
- | Vocabria (cabotegravir oral) / ViiV Healthcare
Journal: Development of an Analytical Method for Determination of Related Substances and Degradation Products of Cabotegravir Using Analytical Quality by Design Principles. (Pubmed Central) - Mar 23, 2022
All method validation results were within selected criteria. The presented method could be used for the development of new pharmaceutical products based on cabotegravir.
- | Edurant (rilpivirine) / J&J, Prezcobix (darunavir/cobicistat) / Gilead, J&J, Tivicay (dolutegravir) / ViiV Healthcare
Trial completion, Trial completion date: Effect on HIV Medications on EPC Cells (clinicaltrials.gov) - Mar 22, 2022
P=N/A, N=22, Completed, Sponsor: Sabyasachi Sen
The presented method could be used for the development of new pharmaceutical products based on cabotegravir. Recruiting --> Completed | Trial completion date: Dec 2020 --> Dec 2021
- | Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Journal: Virus-Mimicking Polymer Nanoparticles Targeting CD169 Macrophages as Long-Acting Nanocarriers for Combination Antiretrovirals. (Pubmed Central) - Mar 19, 2022
Intracellular localization of GM3-presenting PLA NPs in VCCs correlated with retention of intracellular ARV concentrations and sustained inhibition of HIV-1 infection. This work elucidates the design criteria of lipid-coated polymer NPs to utilize CD169 macrophages as cellular drug depots for eradicating the viral reservoir sites or to achieve long-acting prophylaxis against HIV-1 infection.
- || Comtan (entacapone) / Novartis, Orion Corp, Edurant (rilpivirine) / J&J
Review, Journal: Insights into the chemistry and therapeutic potential of acrylonitrile derivatives. (Pubmed Central) - Mar 17, 2022
In this review, diverse synthetic strategies for constructing desired acrylonitriles are discussed, and the different biological activities and medicinal significance of various acrylonitrile derivatives are critically evaluated. The information gathered is expected to provide rational guidance for the development of clinically useful agents from acrylonitriles.
- || Edurant (rilpivirine) / J&J
Enrollment closed: A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years (clinicaltrials.gov) - Mar 16, 2022
P2, N=53, Active, not recruiting, Sponsor: Janssen Sciences Ireland UC
The information gathered is expected to provide rational guidance for the development of clinically useful agents from acrylonitriles. Recruiting --> Active, not recruiting
- |||| Edurant (rilpivirine) / J&J
Observational data: Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV | AIDS Research and Human Retroviruses https://t.co/e1IIjE3Jlw (Twitter) - Mar 16, 2022
- || Tivicay (dolutegravir) / ViiV Healthcare
Retrospective data, Review, Journal, HEOR, Real-world evidence: Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence. (Pubmed Central) - Mar 15, 2022
Recruiting --> Active, not recruiting Treatment with DTG + 3TC or DTG + RPV in clinical practice provides a low rate of VF and a high rate of VS when initiated in virologically suppressed PLHIV with diverse backgrounds.
- || Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Dolutegravir-Based Dual Therapies in HIV Pretreated Patients: A Real-Life Study in Madrid. (Pubmed Central) - Mar 11, 2022
The use of DTG-based dual therapies has increased in real life, showing a favorable effectiveness and safety profile. Treatment costs increased, except for the switch to DTG plus 3TC.
- Edurant (rilpivirine) / J&J
Rilpivirine downregulates p38 and JNK signaling: a part of its hepatoprotective molecular mechanisms () - Mar 9, 2022 - Abstract #AEEH2022AEEH_190;
- Edurant (rilpivirine) / J&J
Inflammation of steatotic hepatocytes is attenuated by the antiretroviral rilpivirine through the inhibition of NF- kB and JNK pathways () - Mar 9, 2022 - Abstract #AEEH2022AEEH_102;
- Edurant (rilpivirine) / J&J
Evidence of the potential Rilpivirine-induced regenerative role in a murine model of CCl4-induced liver injury. () - Mar 9, 2022 - Abstract #AEEH2022AEEH_71;
- Edurant (rilpivirine) / J&J
THE ANTI-INFLAMMATORY EFFECT OF RILPIVIRINE ON MACROPHAGES INVOLVES THE REGULATION OF JAK/STAT SIGNALING () - Mar 9, 2022 - Abstract #AEEH2022AEEH_50;
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Journal: Comparison of efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically suppressed HIV-1-infected patients in a single Italian center: a cohort data analysis. (Pubmed Central) - Mar 8, 2022
This study evaluated the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC (RPV-STR) or DTG/ABC/3TC (DTG-STR) in virologically-suppressed HIV-positive patients in a single Italian centre...No difference in VF rate was observed between the two groups [RR 0.47 95%CI 0.10- 2.14; p=0.335] : Undetectable patients switched to DTG-STR or RPV-STR maintained virologic suppression with a low risk of VF. A higher discontinuation rate was observed with DTG-STR compared to RPV-STR in particular within 3 months from the switch.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Short-cycle therapy in HIV-infected adults: rilpivirine combination 4 days on/3 days off therapy. (Pubmed Central) - Mar 5, 2022
A higher discontinuation rate was observed with DTG-STR compared to RPV-STR in particular within 3 months from the switch. SCT with rilpivirine-containing regimens could be an effective alternative to continuous therapy in selected HIV-infected patients with previous long-term virological suppression.
- || Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
Clinical, Journal: Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting. (Pubmed Central) - Mar 4, 2022
In this large real-life cohort, dolutegravir/rilpivirine and dolutegravir/xTC sustained virological suppression and were associated with a low rate of VF and RAM emergence. Careful virological screening is essential before switching to dolutegravir/rilpivirine in virologically suppressed patients with a history of NNRTI therapy.
- || Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD), Intelence (etravirine) / J&J
Clinical, Journal: Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. (Pubmed Central) - Mar 4, 2022
Deep sequencing significantly increased the detection of resistance-associated mutations. Caution should be used if considering newer-generation NNRTI agents in this setting.
- | Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD)
Journal: Divergent effects of HIV reverse transcriptase inhibitors on pancreatic beta-cell function and survival: Potential role of oxidative stress and mitochondrial dysfunction. (Pubmed Central) - Mar 3, 2022
The deleterious effects observed in beta-cells exposed to efavirenz or rilpivirine may be, at least partially, mediated by oxidative stress and mitochondrial toxicity. These findings provide potential mechanism(s) by which efavirenz and rilpivirine may contribute to the pathogenesis of T2DM and the progression of T2DM to insulin dependency in HIV-infected type 2 diabetics.
- | Edurant (rilpivirine) / J&J
Journal: The frequency of HIV-1 infection and surveillance drug-resistant mutations determination among Iranians with high-risk behaviors, during 2014 to 2020. (Pubmed Central) - Mar 1, 2022
Nevertheless, in one of the patients, V179L mutation was detected which is a rare non-polymorphic mutation and is listed as a rilpivirine (RPV) -associated resistance mutation. The results of the current survey revealed that 2.4% of people with high-risk behaviors are infected with HIV and the level of drug resistance mutations (DRMs) in these people is very low.
- | Preclinical, Journal: Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. (Pubmed Central) - Feb 27, 2022
However, abacavir, dolutegravir, maraviroc, sofosbuvir, tenofovir disoproxil fumarate, and zidovudine had no inhibitory effect...More inhibitors were identified when using digoxin as the ABCB1 probe substrate than when using rhodamine123. However, both approaches had limitations, indicating that inhibitory potency should be tested with at least these two ABCB1 probes.
- | Vocabria (cabotegravir oral) / ViiV Healthcare, Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare
Journal: Cabotegravir (Apretude) for HIV-1 pre-exposure prophylaxis. (Pubmed Central) - Feb 23, 2022
However, both approaches had limitations, indicating that inhibitory potency should be tested with at least these two ABCB1 probes. No abstract available
- || Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Review, Journal: Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review. (Pubmed Central) - Feb 22, 2022
Other long-acting agents are at various stages of development. This review evaluates the current research on the development of long-acting injectable antiretroviral agents for the treatment and prevention of HIV.
- | Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C. (Pubmed Central) - Feb 19, 2022
Moreover, 14b and 16c showed moderate RT enzyme inhibition (IC = 0.14-0.15 μM), which demonstrated that they acted as HIV-1 NNRTIs. Furthermore, 14b and 16c exhibited favorable pharmacokinetic and safety properties, making them excellent leads for further development.
- || Edurant (rilpivirine) / J&J
Long-term effectiveness of rilpivirine-based single-tablet regimens in a seven-year two centers observational cohor… https://t.co/hv1mIXdXD5 (Twitter) - Feb 19, 2022
- | Edurant (rilpivirine) / J&J
Journal: Structural Basis of 2-Phenylamino-4-phenoxyquinoline Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. (Pubmed Central) - Feb 9, 2022
However, 6b and 6d had very low and no cytotoxicity, respectively, to-ward normal embryonic lung (MRC-5) cells. Therefore, the synthesis and biological evaluation of 2-phenylamino-4-phenoxyquinoline derivatives can serve as an excellent basis for the development of highly effective anti-HIV-1 and anticancer agents in the near future.
- Edurant (rilpivirine) / J&J, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Isentress (raltegravir) / Merck (MSD)
PREDICTED IMPACT OF ART SWITCH ON BODY MASS INDEX AMONG WOMEN WITH HIV ([VIRTUAL]) - Feb 7, 2022 - Abstract #CROI2022CROI_660;
Exposure time to zidovudine, efavirenz (EFV) and raltegravir, depressive symptoms and recent recreational drug use were associated with lower BMI; tenofovir alafenamide (TAF), rilpivirine and higher CD4 counts were associated with higher BMI...Of the 353 WWH predicted to achieve ?5% BMI decrease following switch, two regimens accounted for 97.5% of the optimal predicted ART regimens – TAF/emtricitabine(FTC)/EFV (51%) and TAF/FTC/atazanavir/ritonavir (46%) although other factors may preclude their use...However, only 25% of the women were predicted to achieve ?5% decrease in BMI following ART switch. Optimization of other clinical factors may need to be implemented to achieve reductions in BMI among WWH.
- bictegravir (GS-9883) / Gilead
REVERSIBILITY OF CENTRAL NERVOUS SYSTEM ADVERSE EVENTS IN COURSE OF ART ([VIRTUAL]) - Feb 7, 2022 - Abstract #CROI2022CROI_613;
Central nervous system (CNS) adverse events (AE) can occur during various antiretroviral therapies (ART), as well as being a major cause of treatment discontinuation during dolutegravir-containing ART (DTG)...Sixty SNC-AE leading to ART discontinuation were reported, 26/3613 (0.7%) in non DTG-cohorts (2/731 lopinavir, 1/616 atazanavir, 2/721 darunavir, 8/421 rilpivirine, 5/514 raltegravir, 3/339 elvitegravir and 5/211 bictegravir), and 34/1138 (3.1%) in DTG-cohort...AE leading to ART discontinuation were more frequent in DTG than non-DTG treated PLWH. However, most AE resolved after ART switch, with similar frequency in DTG and non-DTG cohorts.
- efavirenz / Generic mfg.
EFAVIRENZ PLASMA LEVELS, COGNITION, AND CENTRAL NERVOUS SYSTEM SIDE EFFECTS ([VIRTUAL]) - Feb 7, 2022 - Abstract #CROI2022CROI_612;
Such marker can be useful to identify Pt who can benefit the most from EFV discontinuation. EFV-but not 8-OH-EFV- Cp were marginally associated with NC performances, suggesting possible different pathways in determining detrimental effects on cognitive function.
- Edurant (rilpivirine) / J&J
CARD8 ACTIVATION BY HIV-1 PR TRIGGERS GSDMD-DEPENDENT AND -INDEPENDENT CELL DEATH ([VIRTUAL]) - Feb 7, 2022 - Abstract #CROI2022CROI_513;
This work reveals that HIV-1-infected cells can undergo CASP1-induced lytic cell death after CARD8 inflammasome activation in GSDMD-dependent and -independent manners. This study broadens our understanding of CARD8 inflammasome-induced cell death and has implications for the clearance of HIV-1 reservoir cells in patients.
- | Edurant (rilpivirine) / J&J, Pifeltro (doravirine) / Merck (MSD), Intelence (etravirine) / J&J
Journal: Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. (Pubmed Central) - Feb 3, 2022
Deep sequencing significantly increased the detection of resistance-associated mutations. Caution should be used if considering newer-generation NNRTI agents in this setting.
- || Edurant (rilpivirine) / J&J
Clinical, Journal: Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. (Pubmed Central) - Jan 27, 2022
A high proportion of adolescents (>92%) remained virologically suppressed up to 48 weeks after switching from EFV to RPV along with no significant change in CD4 cell counts. RPV was well tolerated and associated with improvements in metabolic profiles and executive function.
- || zidovudine / Generic mfg.
PK/PD data, Review, Journal: A Review on Pharmacokinetics properties of antiretroviral drugs to treat HIV-1 infections. (Pubmed Central) - Jan 18, 2022
These drugs are Fuzeon, Selzentry, Complera, Epivir, Retrovir, Emtriva, Ziagen, Edurant, Intelence, Pifeltro, Sustiva, Viramune, Isentress, Genvoya, Tivicay, Reyataz, Prezista, Lexiva, Invirase, Aptivus etc. classified into five major classes: fusion inhibitors, Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Strand transfer inhibitors (INSTIs) and Protease inhibitors (PIs). This review may be helpful for the future development of potent antiretroviral drugs with improved pharmacokinetic properties.
- | Rescriptor (delavirdine mesylate) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Intelence (etravirine) / J&J
Journal: Application of Molecular Docking for the Development of Improved HIV-1 Reverse Transcriptase Inhibitors. (Pubmed Central) - Jan 14, 2022
This review may be helpful for the future development of potent antiretroviral drugs with improved pharmacokinetic properties. In this study, we have identified and proposed some novel molecules with improved binding capacity for HIV RT using a fragment-based approach.
- || Edurant (rilpivirine) / J&J
Clinical: Outcomes of Methadone Maintenance Therapy Combined with Rilpivirine /Efavirenz in Treatment-naive HIV-infected Patients. (Pubmed Central) - Jan 14, 2022
Concomitant administration of RPV does not significantly affect methadone and could decrease withdrawal symptoms. An RPV-based regimen may be used as first-line treatment in IDUs with HIV-infection.
- || Edurant (rilpivirine) / J&J
Clinical, PK/PD data, Journal: Pharmacokinetics and safety of rilpivirine in healthy Japanese subjects and exploration of ethnic sensitivity of rilpivirine pharmacokinetics with physiologically based pharmacokinetic model approach. (Pubmed Central) - Jan 14, 2022
The inter-ethnic difference in rilpivirine exposure was however considered not clinically relevant, since inter-individual variabilities of those intrinsic factors are larger than inter-ethnic ones; and the observed AUC in Japanese subjects was within the range of AUC associated with efficacy and safety in Phase 3 studies. This study results support the use of rilpivirine without dose modification specific to Japanese patients.
- || Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Review, Journal: Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic. (Pubmed Central) - Jan 7, 2022
Clinics will need to address barriers related to management of clinic workflow, procurement, reimbursement, and nonadherence. The aim of this review is to summarize the available safety, efficacy and pharmacokinetic/pharmacodynamic (PK/PD) data of this long-acting (LA) injectable regimen as well as discuss some potential considerations for prescribing and operationalization.